According to the WHO, antimicrobial resistance (AMR) represents a growing threat to global health – one that is placing populations at heightened risk. Paul Owen, global business unit manager – healthcare & life sciences at Mueller Europe, discusses how built environment strategic planning and estates teams can help to manage this growing crisis.
The World Health Organization (WHO) has made its position unmistakably clear. Multidrug- resistant gram-negative bacteria are no longer an emerging concern but a dominant global health threat, with carbapenem resistance representing one of the most critical failures in contemporary antimicrobial therapy.
Organisms once treatable with last line of defence drugs such as meropenem and imipenem are now demonstrating sustained resistance across healthcare systems worldwide.
Cefiderocol (Fetcroja) — a new cephalosporin developed to be active against carbapenem resistant bacteria — was only approved for use in the EU in April 2020 and there are already studies suggesting that high rates of resistance in Cefiderocol are already being tracked.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
